Ayahuasca & Injectable opiates
Ayahuasca is a traditional Amazonian brew composed primarily of two plants: Banisteriopsis caapi and Psychotria viridis. The psychoactive effects of ayahuasca are primarily attributed to the interaction between N,N-dimethyltryptamine (DMT), found in P. viridis, and β-carboline alkaloids such as harmine, harmaline, and tetrahydroharmine (THH) present in B. caapi.
DMT is a potent psychedelic that acts as an agonist at several serotonin receptors, notably the 5-HT₂A receptor, which is closely associated with the modulation of perception, mood, and cognition. Activation of 5-HT₂A receptors by DMT leads to a cascade of intracellular events, including the activation of phospholipase A2 and subsequent release of arachidonic acid, contributing to altered neural activity and the characteristic psychedelic experience.
However, when ingested orally, DMT is rapidly metabolized by the enzyme monoamine oxidase-A (MAO-A) in the gastrointestinal tract, rendering it inactive. The β-carbolines in B. caapi serve as reversible inhibitors of MAO-A, preventing the breakdown of DMT and allowing it to reach the central nervous system. Additionally, THH has been shown to inhibit serotonin reuptake, potentially enhancing serotonergic neurotransmission and contributing to the overall psychoactive profile of ayahuasca.
Injectable opiates, such as morphine, heroin, and fentanyl, exert their effects primarily through agonism at the μ-opioid receptor (MOR), a G-protein-coupled receptor abundantly expressed in the central and peripheral nervous systems. Activation of MOR leads to the inhibition of adenylate cyclase activity, resulting in decreased cyclic AMP levels, and the opening of potassium channels while closing calcium channels. This sequence of events culminates in hyperpolarization of neurons and suppression of neurotransmitter release, effectively dampening nociceptive signaling and producing analgesia.
Beyond analgesia, MOR activation also induces euphoria, respiratory depression, miosis, and sedation. Chronic exposure to opiates can lead to neuroadaptive changes, including receptor desensitization and downregulation, contributing to tolerance and dependence. The mesolimbic dopamine system, particularly the ventral tegmental area and nucleus accumbens, plays a crucial role in the reinforcing properties of opiates, underpinning their high potential for addiction.
The concurrent use of ayahuasca and injectable opiates presents a complex interplay of pharmacodynamic interactions with significant risks. Ayahuasca's β-carbolines inhibit MAO-A, an enzyme also involved in the metabolism of endogenous monoamines and certain exogenous substances. Inhibiting MAO-A can potentiate the effects of other psychoactive compounds, including opiates, potentially leading to enhanced sedation, respiratory depression, and an increased risk of overdose.
Moreover, both ayahuasca and opiates influence serotonergic neurotransmission. While DMT is a direct agonist at serotonin receptors, some opiates have been reported to increase serotonin levels indirectly. The combination could, therefore, elevate the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular abnormalities, autonomic instability, and altered mental status.
From a psychological perspective, the juxtaposition of ayahuasca's profound introspective and often challenging psychedelic experience with the numbing and euphoric effects of opiates may lead to unpredictable mental states. This could exacerbate underlying psychiatric conditions or precipitate acute psychological distress.
Current scientific literature lacks comprehensive studies specifically examining the combined use of ayahuasca and injectable opiates.
All things considered, we recommend avoiding this combination.
Last edited by a moderator: